근위축성 질환 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Muscle Wasting Disorders Market size is expected to reach USD 99.68 Billion in 2034 from USD 26.91 Billion (2025) growing at a CAGR of 15.66% during 2026-2034.

The Global Muscle Wasting Disorders Market is growing steadily due to increasing prevalence of conditions such as muscular dystrophy and cachexia. Rising aging populations and higher incidence of chronic diseases are contributing to demand for effective treatment options. Advances in biotechnology and gene therapy research are supporting the development of innovative therapies. Growing awareness and improved diagnostic capabilities are further driving market expansion.

Key growth drivers include increased investment in rare disease research and supportive regulatory incentives. Pharmaceutical companies are focusing on targeted therapies and personalized medicine approaches. Expanding clinical trials and collaboration between research institutions and biotech firms are accelerating innovation. Additionally, improved healthcare infrastructure in emerging economies is enhancing access to treatment.

Looking ahead, the market is expected to benefit from advancements in gene editing and regenerative medicine. Early diagnosis and supportive care programs will improve patient outcomes. Increased funding for rare disease research will create new growth avenues. As scientific breakthroughs continue, the Global Muscle Wasting Disorders Market is projected to witness sustained development.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Type

• Muscular Dystrophy
• Muscular Atrophy

By Treatment Type

• Medications
• Physical Therapy
• Nutritional Therapy
• Surgery
• Gene Therapy
• Others

By End-user

• Hospitals
• Rehab Centers
• Specialty Clinics
• Others

COMPANIES PROFILED

• Biogen, F HoffmannLa Roche, Novartis, Ionis Pharmaceuticals, Sarepta Therapeutics, Nippon Shinyaku, PTC Therapeutics, Teva Pharmaceutical Industries, Regeneron Pharmaceuticals, Acceleron Pharma Inc
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL MUSCLE WASTING DISORDERS MARKET: BY TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Type
• 4.2. Muscular Dystrophy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Muscular Atrophy Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL MUSCLE WASTING DISORDERS MARKET: BY TREATMENT TYPE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Treatment Type
• 5.2. Medications Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Physical Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Nutritional Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Surgery Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Gene Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.7. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL MUSCLE WASTING DISORDERS MARKET: BY END-USER 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast End-user
• 6.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Rehab Centers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Specialty Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL MUSCLE WASTING DISORDERS MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Type
  • 7.2.2 By Treatment Type
  • 7.2.3 By End-user
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Type
  • 7.3.2 By Treatment Type
  • 7.3.3 By End-user
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Type
  • 7.4.2 By Treatment Type
  • 7.4.3 By End-user
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Type
  • 7.5.2 By Treatment Type
  • 7.5.3 By End-user
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Type
  • 7.6.2 By Treatment Type
  • 7.6.3 By End-user
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL MUSCLE WASTING DISORDERS INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Biogen
  • 9.2.2 F. Hoffmann-La Roche
  • 9.2.3 Novartis
  • 9.2.4 Ionis Pharmaceuticals
  • 9.2.5 Sarepta Therapeutics
  • 9.2.6 Nippon Shinyaku
  • 9.2.7 PTC Therapeutics
  • 9.2.8 Teva Pharmaceutical Industries
  • 9.2.9 Regeneron Pharmaceuticals
  • 9.2.10 Acceleron Pharma Inc